Current progress in beta-amyloid immunotherapy

Current Opinion in Immunology

Volumn 16, Issue 5, 2004, Pages 599-606

  Schenk, Dale ^a   Hagen, Michael ^b   Seubert, Peter ^a  

^a ELAN PHARMACEUTICALS   (United States)

^b WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOTHERAPY; MEDICAL INFORMATION; NEUROSCIENCE; NONHUMAN; REVIEW; T LYMPHOCYTE;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY;

EID: 4444362840     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2004.07.012     Document Type: Review

References (40)

1. D.J. Selkoe, and D. Schenk Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics Annu Rev Pharmacol Toxicol 43 2002 545 584
2. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, and K. Khan Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400 1999 173 177
3. F. Bard, C. Cannon, R. Barbour, R.-L. Burke, D. Games, H. Grajeda, T. Guido, K. Hu, J. Huang, and K. Johnson-Wood Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 6 2000 916 919
4. C. Janus, J. Pearson, J. McLaurin, P.M. Mathews, Y. Jiang, S.D. Schmidt, M.A. Chishti, P. Horne, D. Heslin, and J. French Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease Nature 408 2000 979 982
5. D. Morgan, D.M. Diamond, P.E. Gottschall, K.E. Ugen, C. Dickey, J. Hardy, K. Duff, P. Jantzen, G. DiCarlo, and D. Wilcock Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease Nature 408 2000 982 985
6. E.M. Sigurdsson, B. Permanne, C. Soto, T. Wisniewski, and B. Frangione In vivo reversal of amyloid-β lesions in rat brain J Neuropathol Exp Neurol 59 2000 11 17
7. M.P. Lambert, K.L. Viola, B.A. Chromy, L. Chang, T.E. Morgan, J. Yu, D.L. Venton, G.A. Krafft, C.E. Finch, and W.L. Klein Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies J Neurochem 79 2001 595 605
8. D. Frenkel, N. Kariv, and B. Solomon Generation of auto-antibodies towards Alzheimer's disease vaccination Vaccine 19 2001 2615 2619
9. G.W. Arendash, M.N. Gordon, D.M. Diamond, L.A. Austin, J.M. Hatcher, P. Jantzen, G. DiCarlo, D. Wilcock, and D. Morgan Behavioral assessment of Alzheimer's transgenic mice following long-term Aβ vaccination: task specificity and correlations between Aβ deposition and spatial memory DNA Cell Biol 20 2001 737 744
10. R.B. DeMattos, K.R. Bales, D.J. Cummins, J.C. Dodart, S.M. Paul, and D.M. Holtzman Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease Proc Natl Acad Sci USA 98 2001 8850 8855
11. C. Hock, U. Konietzko, A. Papassotiropoulos, A. Wollmer, J. Streffer, R.C. Von Rotz, G. Davey, E. Moritz, and R.M. Nitsch Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease Nat Med 8 2002 1270 1275
12. J. McLaurin, R. Cecal, M.E. Kierstead, X. Tian, A.L. Phinney, M. Manea, J.E. French, M.H. Lambermon, A.A. Darabie, and M.E. Brown Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4-10 and inhibit cytotoxicity and fibrillogenesis Nat Med 8 2002 1263 1269
13. C. Hock, U. Konietzko, J.R. Streffer, J. Tracy, A. Signorell, B. Muller-Tillmanns, U. Lemke, K. Henke, E. Moritz, and E. Garcia Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease Neuron 38 2003 547 554 Early single-center report of potential clinical benefits of Aβ immunotherapy (AN1792) in AD patients who participated in a multicenter trial.
14. J.-M. Orgogozo, S. Gilman, J.-F. Dartigues, B. Laurent, M. Puel, L.C. Kirby, P. Jouanny, B. Dubois, L. Eisner, and S. Flitman Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization Neurology 61 2003 46 54 A description of the clinical and immunological characteristics of patients who developed encephalitis during a phase 2a trial of Aβ immunotherapy (AN1792).
15. P. Seubert, C. Vigo-Pelfrey, F. Esch, M. Lee, H. Dovey, D. Davis, S. Sinha, M. Schlossmacher, J. Whaley, and C. Swindlehurst Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids Nature 359 1992 325 327
16. B.J. Bacskai, S.T. Kajdasz, M.E. McLellan, D. Games, P. Seubert, D. Schenk, and B.T. Hyman Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy J Neurosci 22 2002 7873 7878
17. B.J. Bacskai, S.T. Kajdasz, R.H. Christie, C. Carter, D. Games, P. Seubert, D. Schenk, and B.T. Hyman Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy Nat Med 7 2001 369 372
18. D.M. Wilcock, G. DiCarlo, D. Henderson, J. Jackson, K. Clarke, K.E. Ugen, M.N. Gordon, and D. Morgan Intracranially administered anti-Aβ antibodies reduce β-amyloid deposition by mechanisms both independent of and associated with microglial activation J Neurosci 23 2003 3745 3751 Demonstration of a two-phase mechanism of amyloid clearance from a mouse model of AD after direct central application of anti-Aβ antibodies.
19. J.C. Dodart, K.R. Bales, K.S. Gannon, S.J. Greene, R.B. DeMattos, C. Mathis, C.A. DeLong, S. Wu, X. Wu, D.M. Holtzman, and S.M. Paul Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model Nat Neurosci 5 2002 452 457
20. Pride MW, Black RW, Hagen M, Dispoto S, Souza V, Giorgio D, Jenkins L, Johnson-Fenno L, Ginsberg R, Daniels M et al.: Evaluation of the cellular immune response in AD patients after immunotherapy with AN1792(QS-21). Poster 201.14 presented at the 33rd Meeting of the Society for Neuroscience, New Orleans, LA, 8-12 November 2003. Abstract available online at http://sfn.scholarone.com.
21. A. Monsonego, V. Zota, A. Karni, J.I. Krieger, A. Bar-Or, G. Bitan, A.E. Budson, R. Sperling, D.J. Selkoe, and H.L. Weiner Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer's disease J Clin Invest 112 2003 415 422
22. Lee M, Bard F, Johnson-Wood K, Lee C, Griffith S, Black R, Seubert P, Schenk D: Properties of anti-Aβ antibodies produced in AD patients following immunization with AN1792. Poster 201.13 presented at the 33rd Meeting of the Society for Neuroscience, New Orleans, LA, 8-12 November 2003. Abstract available online at http://sfn.scholarone.com.
23. D. Schenk, P. Seubert, and R.B. Ciccarelli Immunotherapy with β-amyloid for Alzheimer's disease: a new frontier DNA Cell Biol 20 2001 679 681
24. L.F. Lue, and D.G. Walker Modeling Alzheimer's disease immune therapy mechanisms: interactions of human postmortem microglia with antibody-opsonized amyloid β-peptide J Neurosci Res 70 2002 599 610
25. M. Pfeifer, S. Boncristiano, L. Bondolfi, A. Stalder, T. Deller, M. Staufenbiel, P.M. Matthews, and M. Jucker Cerebral hemorrhage after passive anti-Aβ immunotherapy Science 298 2002 1379
26. R. Furlan, E. Brambilla, F. Sanvito, L. Roccatagliata, S. Olivieri, A. Bergami, S. Pluchino, A. Uccelli, G. Comi, and G. Martino Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice Brain 126 2003 285 291
27. Y. Du, R. Dodel, H. Hampel, K. Buerger, S. Lin, B. Eastwood, K. Bales, F. Gao, H.J. Moeller, and W. Oertel Reduced levels of amyloid β-peptide antibody in Alzheimer disease Neurology 57 2001 801 805
28. B.T. Hyman, C. Smith, I. Buldyrev, C. Whelan, H. Brown, M.X. Tang, and R. Mayeux Autoantibodies to amyloid-β and Alzheimer's disease Ann Neurol 49 2001 808 810
29. R. Dodel, H. Hampel, C. Depboylu, S. Lin, F. Gao, S. Schock, S. Jackel, X. Wei, K. Buerger, and C. Hoft Human antibodies against amyloid β peptide: a potential treatment for Alzheimer's disease Ann Neurol 52 2002 253 256
30. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S: Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology 2004, in press. The first full clinical trial report of the use of Aβ immunotherapy (AN1792) in patients with AD.
31. Nicoll JAR, D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R.O. Weller Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report Nat Med 9 2003 448 452 The first report of amyloid clearance from the brain of an AD patient after treatment with Aβ immunotherapy (AN1792).
32. B. Solomon, R. Koppel, D. Frankel, and E. Hanan-Aharon Disaggregation of Alzheimer β-amyloid by site-directed mAb Proc Natl Acad Sci USA 94 1997 4109 4112
33. H.L. Weiner, C.A. Lemere, R. Maron, E.T. Spooner, T.J. Grenfell, C. Mori, S. Issazadeh, W.W. Hancock, and D.J. Selkoe Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease Ann Neurol 48 2000 567 579
34. I. Ferrer, M. Boada Rovira, M.-L. Sánchez Guerra, M.-J. Rey, and F. Costa-Jussá Neuropathology and pathogenesis of encephalitis following amyloid-immunization in Alzheimer's disease Brain Pathol 14 2004 11 20 Report of amyloid clearance from the brain of an AD patient after treatment with Aβ immunotherapy (AN1792).
35. D. Schenk Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning Nat Rev Neurosci 3 2002 824 828
36. F. Bard, R. Barbour, C. Cannon, R. Carretto, M. Fox, D. Games, T. Guido, K. Hoenow, K. Hu, and K. Johnson-Wood Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathy Proc Natl Acad Sci USA 100 2003 2023 2028
37. F.L. Heppner, I. Arrighi, U. Kalinke, and A. Aguzzi Immunity against prions? Trends Mol Med 7 2001 477 479
38. F.L. Heppner, C. Musahl, I. Arrighi, M.A. Klein, T. Rulicke, B. Oesch, R.M. Zinkernagel, U. Kalinke, and A. Aguzzi Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies Science 294 2001 178 182
39. D. Peretz, R.A. Wiliamson, K. Kaneko, J. Vergara, E. Leclerc, G. Schmitt-Ulms, I.R. Mehlhorn, G. Legname, M.R. Wormald, and P.M. Rudd Antibodies inhibit prion propagation and clear cell cultures of prion infectivity Nature 412 2001 739 743
40. E.M. Sigurdsson, D.R. Brown, M. Daniels, R.J. Kascsak, R. Kascsak, R. Carp, H.C. Meeker, B. Frangione, and T. Wisniewski Immunization delays the onset of prion disease in mice Am J Pathol 161 2002 13 17